$TWST

Cho Dennis sold $222K of TWST

Cho Dennis (See Remarks) sold 1,598 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.22M total) on 2026-08-21.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect price, but provides transparency for investors monitoring insider behavior.

02

Market read

Routine insider sale with limited trading relevance; serves mainly as a compliance disclosure.

03

What to watch

The sale may be for personal liquidity needs unrelated to company outlook.

Relevance 4/10Novelty 4/10Timing: post‑market filing on 2026‑08‑25

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Officer Cho Dennis sold 1,598 shares of Twist Bioscience for $222,227 on 2026-08-21.

Expected impact

Minimal short‑term pressure; unlikely to move the stock materially.

Evidence & confidence

The sale size ($222K) is small relative to market cap and insider holdings, and no unusual circumstances are indicated.

Market effects

None; Twist Bioscience operates in synthetic biology, but the transaction is too small to affect sector sentiment.

None; the filing is U.S.‑based and does not influence regional markets.

None; the event is isolated to a single micro‑cap stock.

Counterpoint

If the officer is reducing exposure, it could signal concerns about near‑term performance.

Key entities

  • Cho Dennis

    Officer of Twist Bioscience who sold shares.

  • Twist Bioscience Corp

    Biotechnology company listed on NASDAQ under ticker TWST.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.